Mar 24, 2009 - Celsion Corporation, a leading oncology drug development company, today announced that the U.S. FDA) has granted orphan drug designation for its lead compound, ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.
the details can be read here.
No comments:
Post a Comment